Education Library

Resources for Health Care Professionals

Filter Results

Condition

Audience

Topic

Type

July 8, 2021

Protected PCI for Superior Long-Term Outcomes

Gregg Stone, MD, and Duane Pinto, MD, host this panel discussion from SCAI 2021 of Protected PCI and diagnosis and treatment of high-risk and complex coronary disease.

May 20, 2021

CRT 2021: PROTECT IV and Beyond with Rajan Patel, MD

Rajan Patel, MD, discusses clinical data supporting Impella® use in Protected PCI and cardiogenic shock at the CRT 2021 virtual annual symposium. 

April 15, 2021

First Patient Enrolled in PROTECT IV Randomized Controlled Trial of Impella® Heart Pumps

The PROTECT IV RCT will leverage advancements in technology and best practices learned since the completion of the PROTECT II RCT and the FDA pre-market approval for Impella 2.5® for high-risk PCI. 

February 23, 2021

Impact of Impella® on Dissected Coronary Artery Hemodynamics

Kiyotake Ishikawa, MD, discusses his paper on the impact of Impella on dissected coronary artery hemodynamics in a porcine model.

October 27, 2020

Intermediate-Term Left Ventricular Function Following Non-Emergent Impella Protected PCI: Restore EF Study

Mitul Patel, MD, shares intermediate-term results from RESTORE EF, a multicenter, prospective, observational, single-arm study that is still actively enrolling patients

October 27, 2020

Results From PROTECT III, the Largest Prospective Multi-Center Single-Arm Study

Jeffrey Moses, MD, presents results from PROTECT III, the largest prospective study of Impella® for high-risk PCI in the real world.

May 29, 2020

No Increase in Mortality in Impella®-Supported Nonemergent High-Risk PCI

No increase in mortality seen in patients undergoing nonemergent high-risk Protected PCI in recent paper by Samin Sharma, MD, and colleagues.

February 24, 2020

Amin et al. 

The objective of the analysis, as stated in Amin et al., was “to describe the trends in Impella® use; variation in Impella use and its outcomes over 13 years.

February 3, 2020

Bleeding and Vascular Complications: A Look at Impella® Data Over Time

Daniel Raess, MD, describes how Impella® bleeding and vascular complication data has evolved over time and how it compares to data for other forms of mechanical circulatory support.

January 6, 2020

Discover New Data on Protected PCI versus Bailout PCI

Alexander Truesdell, MD, discusses Protected PCI versus bailout PCI using data from the cVAD Study and the PROTECT III study. 

November 26, 2019

PROTECT Series of Clinical Studies Provides Mounting Evidence for Impella® Support in High-risk PCI

Impella “reduced major adverse events, critical care and readmission length of stay, and readmission cost over the 90-day EOC (episode of care), and was determined to be cost-effective over the long-term.”

November 17, 2019

Amin Analysis: Review of Trends, Variation and Outcomes in Impella® Use

Seth Bilazarian, MD, reviews the shortcomings of the Amin, et al., analysis presented at AHA 2019.

November 15, 2019

George Vetrovec, MD, Discusses Impella® Cost-Effectiveness

Dr. George Vetrovec discusses data showing the cost-effectiveness of PVADs, including Impella, in high-risk PCI and cardiogenic shock. 

October 31, 2019

Contemporary Landscape of PCI and RESTORE EF

Ehtisham Mahmud, MD, discusses the landscape of contemporary PCI and introduces the RESTORE EF study. 

September 24, 2019

RESTORE EF Study: Impact on EF at 60-180 days after High-risk PCI 

Jason Wollmuth, MD and Thom Dahle, MD discuss the RESTORE EF Study, which evaluates EF and clinical status at 60-180 days after high-risk PCI with Impella® support.

NPS-1674